CN117083061A - 用于治疗癌症的组合物和方法 - Google Patents

用于治疗癌症的组合物和方法 Download PDF

Info

Publication number
CN117083061A
CN117083061A CN202280024006.5A CN202280024006A CN117083061A CN 117083061 A CN117083061 A CN 117083061A CN 202280024006 A CN202280024006 A CN 202280024006A CN 117083061 A CN117083061 A CN 117083061A
Authority
CN
China
Prior art keywords
cancer
methylenediamine
pharmaceutically acceptable
subject
dihydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280024006.5A
Other languages
English (en)
Chinese (zh)
Inventor
孔彦平
刘锦红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN117083061A publication Critical patent/CN117083061A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280024006.5A 2021-02-02 2022-01-28 用于治疗癌症的组合物和方法 Pending CN117083061A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144690P 2021-02-02 2021-02-02
US63/144,690 2021-02-02
PCT/US2022/014379 WO2022169690A1 (en) 2021-02-02 2022-01-28 Composition and methods for treating cancer

Publications (1)

Publication Number Publication Date
CN117083061A true CN117083061A (zh) 2023-11-17

Family

ID=82742455

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280024006.5A Pending CN117083061A (zh) 2021-02-02 2022-01-28 用于治疗癌症的组合物和方法

Country Status (8)

Country Link
US (1) US20240099992A1 (https=)
EP (1) EP4288040A4 (https=)
JP (1) JP2024506999A (https=)
KR (1) KR20230142733A (https=)
CN (1) CN117083061A (https=)
AU (1) AU2022218110A1 (https=)
CA (1) CA3209477A1 (https=)
WO (1) WO2022169690A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560522A1 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
JPWO2011002026A1 (ja) * 2009-06-30 2012-12-13 国立大学法人 熊本大学 アミロイド線維形成抑制剤及びその利用
RU2417999C2 (ru) * 2009-07-13 2011-05-10 Закрытое Акционерное Общество "Ива Фарм" БИЯДЕРНЫЕ КООРДИНАЦИОННЫЕ СОЕДИНЕНИЯ БИОЛОГИЧЕСКИ АКТИВНЫХ d-ЭЛЕМЕНТОВ С АЛИФАТИЧЕСКИМИ ТИОЛАМИ КАК СРЕДСТВА ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
JP2011084541A (ja) * 2009-10-19 2011-04-28 Ltt Bio-Pharma Co Ltd 低分子薬物含有ナノ粒子
CA3064486C (en) 2017-04-20 2023-08-01 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives
GB201804924D0 (en) * 2018-03-27 2018-05-09 Univ Oxford Innovation Ltd Radiolabelled compound

Also Published As

Publication number Publication date
KR20230142733A (ko) 2023-10-11
AU2022218110A1 (en) 2023-08-17
US20240099992A1 (en) 2024-03-28
CA3209477A1 (en) 2022-08-11
JP2024506999A (ja) 2024-02-15
EP4288040A1 (en) 2023-12-13
EP4288040A4 (en) 2025-01-08
WO2022169690A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
EP3003296B1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
TWI620565B (zh) 治療及預防移植物抗宿主病之方法
TWI551288B (zh) Antimicrobial activity enhancer for chemotherapeutic agents
JP2017078056A (ja) 有機セレン化合物の組成物およびその使用方法
EP4424316A1 (en) Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
EP3684345B1 (en) Treatment of drug resistant gliomas
CN117083061A (zh) 用于治疗癌症的组合物和方法
US20250275938A1 (en) Compositions and methods for treatment of cancer
CN106163515A (zh) 抗癌剂和副作用减轻剂
HK40103289A (zh) 用於治疗癌症的组合物和方法
US20240307373A1 (en) Methods of use and compositions of bisbenzylisoquinolines for the treatment of malignancies
KR102810776B1 (ko) N-포르밀트립톨린을 유효성분으로 포함하는 방사선 내성 암의 예방, 개선 또는 치료용 조성물
EP3417864A1 (en) Immunosuppression weaning agent and use thereof
CA3074102C (en) Treatment of drug resistant gliomas
US20230218659A1 (en) Selenium-Based Compositions and Therapeutic Methods
JP2025177165A (ja) アントラサイクリン系抗癌剤により誘発される心毒性を予防及び／又は治療するための組成物
WO2025241125A1 (zh) 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途
KR20250100273A (ko) 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법
JP2026020821A (ja) 代謝抑制による抗腫瘍剤
KR20210091054A (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
KR20220067765A (ko) 템시로리무스를 유효성분으로 포함하는 면역증진제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103289

Country of ref document: HK